Biochemical Pharmacology volume 80, issue 5, P584-591 2010 DOI: 10.1016/j.bcp.2010.05.001 View full text
|
|
Share
Con Sullivan, Cong Peng, Yaoyu Chen, Dongguang Li, Shaoguang Li

Abstract: Inhibition of BCR-ABL with kinase inhibitors has become a well-accepted strategy for targeted therapy of Philadelphia-positive (Ph+) chronic myeloid leukemia (CML), and has been shown to be highly effective in controlling the disease. However, BCR-ABL kinase inhibitors do not efficiently kill leukemic stem cells (LSCs), indicating that this therapeutic strategy does not lead to a cure of CML. Development of curative therapies of CML require the identification of genes/pathways that play critical roles in surv…

expand abstract